

Patient: **COX, MELISSA REIGH HAZEL**

Lab No: **2022-2U6540197**



Age: 26 years Gender: F

Reference #:

Date of Birth: Jun 02 1995

Patient ID: 20222U6540197

HC #: **2504835873**

Referring Site ID:

Patient's Phone: (647) 461-2232

Date of Service: Feb 23 2022 09:09

Address: 100 International Blvd.
Toronto, Ontario
Canada M9W 6J6

Ordered by: LASKIN DR. C.

Reported on: Feb 24 2022 12:41

Telephone: (877) 849-3637
Toll Free: (877) 849-3637
Fax: (905) 795-9891

Copy To:

Test	Flag	Result	Reference Range - Units	Lab Lic. #
Hematology				
WBC		6.6	4.0 - 11.0	x E9/L #5407
RBC		4.16	4.00 - 5.10	x E12/L
Hemoglobin		126	120 - 160	g/L
Hematocrit		0.380	0.350 - 0.450	L/L
MCV		91	80 - 100	fL
MCH		30.3	27.5 - 33.0	pg
MCHC		332	305 - 360	g/L
RDW		11.7	11.5 - 14.5	%
Platelet Count		318	150 - 400	x E9/L
Differential				
Neutrophils		4.4	2.0 - 7.5	x E9/L
Lymphocytes		1.5	1.0 - 3.5	x E9/L
Monocytes		0.6	0.2 - 1.0	x E9/L
Eosinophils		0.2	0.0 - 0.5	x E9/L
Basophils		0.1	0.0 - 0.2	x E9/L
Immature Granulocytes		0.0	0.0 - 0.1	x E9/L
Nucleated RBC		0		/100 WBC

Immunohematology

Blood Grouping (Prenatal)

ABO Group
Rh

O
NEGATIVE

If pregnant, this patient is a possible candidate for Rh immunoglobulin.

Blood Group Antibody Screen

NOT DETECTED

No red cell antibodies detected by screening at 37 degrees C.

These results are intended for prenatal care/community monitoring and should not be used for transfusion purposes.

Comment

If prenatal assessment, a copy of this report should be forwarded to the transfusion service at the hospital where this patient will be delivering.

#5687

One or more results on this report are not accessible to you via my ehealth; please contact the ordering Health Care Provider for more information.

Patient: COX, MELISSA REIGH HAZEL

Lab No: 2022-2U6540197



Age: 26 years Gender: F

Reference #:

Date of Birth: Jun 02 1995

Patient ID: 20222U6540197

HC #: 2504835873

Referring Site ID:

Patient's Phone: (647) 461-2232

Date of Service: Feb 23 2022 09:09

Ordered by: LASKIN DR. C.

Reported on: Feb 24 2022 12:41

Address: 100 International Blvd. Toronto, Ontario Canada M9W 6J6

Telephone: (877) 849-3637

Toll Free: (877) 849-3637

Fax: (905) 795-9891

Copy To:

Test	Flag	Result	Reference Range - Units	Lab Lic. #
------	------	--------	-------------------------	------------

Urinalysis

Urinalysis Chemical

#5407

Collection Date		23-FEB-2022		
Collection Time		09:09		
Appearance		CLEAR	Clear	
		New method implemented in October 2021. Reporting categories updated, reference intervals remain the same.		
Colour		YELLOW	Yellow	
Specific Gravity		1.025		
pH		5.5	5.0 - 8.0	
Protein		NEGATIVE	Negative	g/L
Glucose	HI	28	Negative	mmol/L
Ketones		NEGATIVE	Negative	mmol/L
Blood	HI	TRACE	Negative	RBC/uL
Nitrite		NEGATIVE	Negative	
Leukocytes		NEGATIVE	Negative	WBC/uL

Please see <https://tests.lifelabs.com/Urinalysis/URINALYSIS-CHEMICAL.aspx?s=1> for alternative reporting units.

General Chemistry

Glucose Random	HI	10.3	3.6 - 7.7	mmol/L
		Recommend follow-up with Fasting Glucose and/or HbA1c as per 2013 CDA Guidelines (Can J Diabetes 2013;37(suppl 1):S1-S212).		
Hemoglobin A1C/Total Hemoglobin	HI	8.7	<6.0	%
		Diabetes Canada 2018 Guidelines:		

		Screening and Diagnosis: < 5.5 % Normal		
		5.5% - 5.9 % At risk		
		6.0% - 6.4 % Prediabetes		
		>OR= 6.5 % Diabetes Mellitus		
		If HbA1c >OR= 6.5 % and asymptomatic, confirm using Fasting Glucose, HbA1c or 75g OGTT.		

		Monitoring: <OR= 7.0 %		
		Target in adults without comorbidities. Other targets may be more appropriate in children, elderly and patients with comorbidities.		

		Results may not accurately reflect mean blood glucose in patients with hemoglobin variants, disorders associated with abnormal erythrocyte turnover, severe renal and liver disorders.		
Sodium		140	135-145	mmol/L

One or more results on this report are not accessible to you via my ehealth; please contact the ordering Health Care Provider for more information.

FINAL RESULTS

IMPORTANT:

This report contains confidential information intended for view by authorized person(s) only and should be disposed of securely (e.g. shredding) before discarding.

Note to Health Care Providers: This report has been printed by the patient.

Note to patients:

Please contact your Health Care Provider if you have any questions regarding the results on this report.

Patient: **COX, MELISSA REIGH HAZEL**

Lab No: **2022-2U6540197**



Age: 26 years Gender: F

Reference #:

Date of Birth: Jun 02 1995

Patient ID: 20222U6540197

HC #: **2504835873**

Referring Site ID:

Patient's Phone: (647) 461-2232

Date of Service: Feb 23 2022 09:09

Ordered by: LASKIN DR. C.

Reported on: Feb 24 2022 12:41

Address: 100 International Blvd.
Toronto, Ontario
Canada M9W 6J6

Telephone: (877) 849-3637

Toll Free: (877) 849-3637

Fax: (905) 795-9891

Copy To:

Test	Flag	Result	Reference Range - Units	Lab Lic. #
General Chemistry				
Potassium		4.3	3.5-5.2 mmol/L	
Creatinine		57	50-100 umol/L	
Glomerular Filtration Rate (eGFR)		>120		
Normal eGFR is described as greater than or equal to 90 ml/min/1.73 m2.				
For patients of African descent, the reported eGFR must be multiplied by 1.15.				
Effective May 4 2015, eGFR is calculated using the CKD-EPI 2009 equation.				
KDIGO 2012 guidelines highlight the importance of eGFR and urine albumin creatinine ratio (ACR) in screening, diagnosis and management of CKD. Results for eGFR should be interpreted in concert with ACR.				
Albumin		44	35-52 g/L	
Bilirubin Total		5	<20 umol/L	
Alkaline Phosphatase	HI	149	35-120 U/L	
Alanine Aminotransferase		9	<36 U/L	
Random Urine Chemistry				
Protein Creatinine Ratio Urine				
Protein (Urine)		<0.10	<0.15 g/L	
Creatinine (Urine)		9.7	2.5-20.0 mmol/L	
Protein/Creatinine			Unable to calculate Protein/Creatinine Ratio as the concentration of Protein is less than 0.10 g/L, the lower detection limit of the assay.	
Albumin Creatinine Ratio Urine				
Albumin (Urine)		13	mg/L	
Creatinine (Urine)		9.6	2.5-20.0 mmol/L	
Albumin/Creatinine		1.4	< 2.0 mg/mmol	
Thyroid Function				
Thyroid Stimulating Hormone [TSH]		1.01	0.32-4.00 mIU/L	

One or more results on this report are not accessible to you via my ehealth; please contact the ordering Health Care Provider for more information.

Patient: **COX, MELISSA REIGH HAZEL**

Lab No: **2022-2U6540197**



Age: 26 years Gender: F

Reference #:

Date of Birth: Jun 02 1995

Patient ID: 20222U6540197

HC #: **2504835873**

Referring Site ID:

Patient's Phone: (647) 461-2232

Date of Service: Feb 23 2022 09:09

Ordered by: LASKIN DR. C.

Reported on: Feb 24 2022 12:41

Address: 100 International Blvd.
Toronto, Ontario
Canada M9W 6J6

Telephone: (877) 849-3637

Toll Free: (877) 849-3637

Fax: (905) 795-9891

Copy To:

Test	Flag	Result	Reference Range - Units	Lab Lic. #
------	------	--------	-------------------------	------------

Pituitary Function

Follicle Stimulating Hormone [FSH]		4.0	IU/L
------------------------------------	--	-----	------

Follitropin (FSH) female reference intervals

Follicular:	3.0-8.0	IU/L
Mid-cycle:	3.0-22.0	IU/L
Luteal:	1.5-5.5	IU/L
Post-menopausal:	27.0-133.0	IU/L

Luteinizing Hormone [LH]		5.0	IU/L
--------------------------	--	-----	------

Lutropin (LH) female reference intervals

Follicular:	2.0-12.0	IU/L
Mid-cycle:	8.0-90.0	IU/L
Luteal:	1.0-14.0	IU/L
Post-menopausal:	5.0-62.0	IU/L

Prolactin		11.2	5.0-27.0 ug/L
-----------	--	------	---------------

Reproductive and Gonadal

Choriogonadotropin [HCG]		<1	IU/L
--------------------------	--	----	------

Female (Non pregnant) < 5
Gestational Age:

=====

< 1 week	5 - 50
1 - 2 weeks	50 - 500
2 - 3 weeks	100 - 5000
3 - 4 weeks	500 - 10,000
4 - 5 weeks	1000 - 50,000
5 - 6 weeks	10,000 - 100,000
6 - 8 weeks	15,000 - 200,000
8 - 12 weeks	10,000 - 100,000

HCG values are based on rough estimate of gestational age since conception and should be used only in conjunction with reliable and accurate estimations of gestational age based on sonography or LMP.

Anti-Mullerian Hormone		33.9	6.4-70.3 pmol/L
------------------------	--	------	-----------------

AMH levels < 5.0 pmol/L have a 63% probability of an antral follicle count (AFC) < 8.
AMH levels > 16.2 pmol/L have a 75% probability of an AFC > 15.(Fertil Steril 2015;103:1074-1080)

#5687

One or more results on this report are not accessible to you via my ehealth; please contact the ordering Health Care Provider for more information.

FINAL RESULTS

IMPORTANT:

This report contains confidential information intended for view by authorized person(s) only and should be disposed of securely (e.g. shredding) before discarding.

Note to Health Care Providers: This report has been printed by the patient.

Note to patients:

Please contact your Health Care Provider if you have any questions regarding the results on this report.

Patient: **COX, MELISSA REIGH HAZEL**

Lab No: **2022-2U6540197**



Age: 26 years Gender: F

Reference #:

Date of Birth: Jun 02 1995

Patient ID: 20222U6540197

HC #: **2504835873**

Referring Site ID:

Patient's Phone: (647) 461-2232

Date of Service: Feb 23 2022 09:09

Ordered by: LASKIN DR. C.

Reported on: Feb 24 2022 12:41

Address: 100 International Blvd.
Toronto, Ontario
Canada M9W 6J6

Telephone: (877) 849-3637

Toll Free: (877) 849-3637

Fax: (905) 795-9891

Copy To:

Test	Flag	Result	Reference Range - Units	Lab Lic. #
------	------	--------	-------------------------	------------

Reproductive and Gonadal

Estradiol

111

pmol/L

#5407

Estradiol adult female reference intervals

Follicular: 77-921 pmol/L

Mid-cycle: 139-2382 pmol/L

Luteal: 77-1145 pmol/L

Post-menopausal: <103 pmol/L

NOTE: Fulvestrant has been shown to interfere with estradiol testing by this direct immunoassay. Results for patients taking this medication may be falsely elevated to a clinically-significant degree.

Some steroidal aromatase inhibitors are structurally related to estradiol and may interfere with some direct immunoassays.

Progesterone

1.2

nmol/L

Progesterone adult female reference intervals

Follicular: <1.7 nmol/L

Luteal: 4.0-50.0 nmol/L

Post-menopausal: <1.7 nmol/L

Serology Non-Viral

Hepatitis B

Hepatitis B Surface Ag [HBsAg]

NOT DETECTED

New reagent formulation as of June 2, 2021 has reduced interference from high doses of biotin.

One or more results on this report are not accessible to you via my ehealth; please contact the ordering Health Care Provider for more information.

FINAL RESULTS

IMPORTANT:

This report contains confidential information intended for view by authorized person(s) only and should be disposed of securely (e.g. shredding) before discarding.

Note to Health Care Providers: This report has been printed by the patient.

Note to patients:

Please contact your Health Care Provider if you have any questions regarding the results on this report.